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Abstract
Cytochrome P450 2A6 is involved in the metabolism of nicotine and the activation of carcinogenic
nitrosamines. It is expressed in the liver and several extrahepatic tissues including lung and nasal mucosa.
Genetic variability of CYP2A6 is considerable and has clinical implications. CYP2A6 polymorphisms are
suggested to influence smoking behavior and cancer risk (Pianezza et al., 1998 and Kamataki et al., 1999). The
clearance of letrozole, an aromatase inhibitor, can be altered by CYP2A6 variants (Desta et al., 2010). While
the relationship between CYP2A6 polymorphisms and nicotine metabolism is established, the impact of
dietary constituents and other xenobiotics as CYP2A6 modulators is less understood. With this in mind,
cinnamic aldehyde and related analogs were assessed for their capacity to modulate CYP2A6 activity in vitro.
Cinnamic aldehyde is the major constituent in cinnamon oil and is present in a variety of foods, gums,
cosmetic products, and supplements. Of three cinnamic derivatives cinnamic aldehyde displayed the greatest
potency in IC50 studies (IC50 = 7.0 µM; IC50 = 354.4 µM and IC50 > 2500 µM for cinnamic alcohol and
cinnamic acid, respectively). Cinnamic aldehyde also exhibited time and NADPH dependent inhibition of
coumarin hydroxylase activity (KI = 21.0 µM and kinact = 0.038 min-1). Molecular modeling identified five
amino acids interacting with cinnamic aldehyde and threonine 305 was identified as a potential site for
covalent modification by a reactive metabolite generated from activation of cinnamic aldehyde. The
investigation of this model Michael acceptor molecule will facilitate the understanding of the molecular
mechanism of CYP2A6 inactivation by phenylpropanoids.
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Results 
1. Inactivation of human CYP2A6 mediated coumarin hydroxylase activity following pre-
incubation with trans-cinnamic aldehyde and NADPH.  Data points are the average of 
at least three experiments conducted on separate days.   
 
 
 
 
 
 
 
 
 
2. Remaining coumarin hydroxylase activity following 18 minute preincubation.  Values 
are the average of three trials conducted on separate days. 
   Pre-Incubation Components    % Control Activity 
   2A6 Supersomes, reductase,     100 (6.1 ± 0.4 pmol/min/pmol) 
     and cytochrome b5  
    + NADPH           91.6 ± 3.5      
     + 10 µM  Cinn. Ald.,  + NADPH       84.1 ± 4.2 
      + 20 µM  Cinn. Ald.,  + NADPH      69.3 ± 10.8  
     + 40 µM  Cinn. Ald.,  + NADPH      56.6 ± 3.9 
    + 80 µM  Cinn. Ald.          85.2 ± 3.6 
    + 80 µM  Cinn. Ald.,  + NADPH        41.1 ± 3.5  
    + 80 µM  Cinn. Ald.,  + NADPH + 5 mM GSH   57.4 ± 9.5 
    + 120 µM Cinn. Ald., + NADPH      34.9 ± 3.4 
 
3. Cinnamic aldehyde is the most potent inhibitor of the cinnamic derivatives tested. 
 
 
          Cinnamic Derivative  IC50 (µM) 
            
           Aldehyde   6.9 ± 1.2 
           Alcohol      354.4 ± 1.4 
           Acid    > 2500 
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Introduction 
Modulators and probes of CYP2A6 : 
 A relationship between CYP2A6 genetic polymorphisms and nicotine metabolism has 
been described and the influence of social environment (e.g., peer group, family, etc.) 
on smoking behavior has also been studied1-3.  Information describing the impact of 
dietary constituents as CYP2A6 modulators is less available.   
 The functional impact of amino acid changes resulting from genetic polymorphisms  
and the structural basis for CYP2A6 substrate/product selectivity has yet to be 
elucidated. In an effort to shed light on these topics, cinnamic aldehyde and related 
analogs were assessed for their potential to probe and modulate CYP2A6 activity.  
CYP2A6 is the major human nicotine metabolizing enzyme: 
 CYP2A6 is the major human enzyme catalyzing the initial oxidation of nicotine, which 
is a primary route of clearance1.  There is evidence CYP2A6 genetic polymorphisms 
influence smoking behaviors (e.g., slow metabolizers exhibit decreased smoking 
intensity)2.  CYP2A6 is also involved in the activation of carcinogenic nitrosamines and 
the N-dealkylation of letrozole (Femara®), an aromatase inhibitor used in the 
treatment of breast cancer in postmenopausal women4-6. 
 
 
 
 
 
Cinnamic aldehyde and related analogs as probes of CYP2A6:  
 Cinnamic aldehyde is the major constituent in cinnamon oil and is present in a variety 
supplements and herbal medicines as well as foods, gums, and cosmetic products. 
 Crystal structures of CYP2A6 indicate the active site is relatively small compared to 
other drug metabolizing CYPs and this is often reflected in CYP2A6 substrate 
selectivity.  That is, CYP2A6 substrates are generally low molecular weight molecules.  
We hypothesized that dietary phenylpropanoids such as cinnamic aldehyde may serve 
as probes of CYP2A6 function-structure relationships.    
Discussion 
1. trans-Cinnamic aldehyde is a time-dependent inhibitor of CYP2A6 (KI = 17.2 µM and kinact= 
0.037 min-1).  
2. The NADPH requirement for time-dependent inhibition of CYP2A6 by cinnamic aldehyde and 
trapping of a presumptive metabolite by GSH indicates that a metabolite of cinnamic 
aldehyde, rather than the parent molecule, is the inactivating agent. 
3. 2,3-epoxy cinnamic aldehyde is proposed as a reactive metabolite that results in CYP2A6 
inactivation.     
 
 
 
4. Docking of cinnamic aldehyde and 2,3-epoxy cinnamic aldehyde identified F118, G301, N297, 
and T305 as residues interacting with both probe molecules, with T305 serving as a potential 
site for covalent modification by 2,3-epoxy cinnamic aldehyde.   
Objectives 
1. Assess the potential for cinnamic derivatives to modulate human CYP2A6 activity and  
to test the most potent inhibitors for mechanism based inactivation.   
2. Dock cinnamic derivatives with CYP2A6 to identify prospective protein-substrate 
interactions.  
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●    Buffer 
◊    NADPH 
■   10 µM Cin. Ald.  
*   20 µM Cin. Ald. 
▲    40 µM Cin. Ald. 
o 80 µM Cin. Ald. 
♦   120 µM Cin. Ald.  
4. NADPH is required for time-dependent inhibition of CYP2A6 by cinnamic aldehyde. 
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◊  NADPH 
■  80 µM Cin. Ald.  
o  80 µM Cin. Ald., + NADPH 
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Pre-incubation period (minutes) 
5. Molecular docking of 
cinnamic aldehyde (A), 
cinnamic acid (B), 
cinnamic alcohol (C), and 
the proposed 2,3-epoxy 
cinnamic aldehyde (D) 
into the CYP2A6 crystal 
structure (1Z10). The 
docked molecule is 
displayed in green, the 
macromolecule in cyan, 
the heme in red, and 
identified interacting 
amino acids in yellow 
(AutoDock 4.2, Release 
4.2.2.1, The Scripps 
Research Institute, La 
Jolla, CA). 
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